icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
Jzsr0e0KrCESzdRk